Defining the Impact of Cytokine Signaling in Alzheimer’s Disease
About the Research Project
Program
Award Type
Standard
Award Amount
$200,000
Active Dates
July 01, 2024 - June 30, 2026
Grant ID
A2024030F
Mentor(s)
Anna Molofsky, MD, PhD, University of California, San Francisco
Goals
This project aims to determine the mechanistic impact of a key immune pathway in AD pathology, potentially leading to novel approaches for AD immunotherapies.
Summary
Immune signals regulate brain homeostasis and are also a major driver of Alzheimer’s disease pathology. This proposed study aims to investigate how astrocyte-microglia crosstalk via IL-33 cytokine impacts Alzheimer’s disease pathology and behavior. This work will determine the mechanistic impact of a key immune pathway in AD pathology and suggest the novel hypothesis that ECM disruption is linked to AD pathology.
Unique and Innovative
I will use strategies for targeted manipulation of cytokine signaling. Viral-mediated cytokine delivery by glial cells will be utilized as a gain-of-function strategy. The study will provide new insight into the mechanisms of glial involvement in amyloid pathology.
Foreseeable Benefits
This work will determine the mechanistic impact of a key immune pathway in Alzheimer’s disease pathology. The study will provide new insights into the mechanisms of tissue damage and how immune signals impact amyloid pathology.
Related Grants
Alzheimer's Disease Research
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Defining Immunometabolic Contributions to Cognitive Impairment in Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Caleb Bailey, PhD
Current Organization
University of Kentucky Research Foundation
Alzheimer's Disease Research
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Understanding the Link Between Alzheimer's Disease Risk Genes and Immune Responses in the Brain
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Amanda McQuade, PhD
Current Organization
University of California, San Francisco
Alzheimer's Disease Research
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital
Developing a Noninvasive Gene Therapy for Alzheimer's Disease
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Dominika Pilat, PhD
Current Organization
Massachusetts General Hospital